Kamada LTD., a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, was granted an Orphan Drug Designation for its Alpha-1 Antitrypsin (AAT) product to treat type 1 diabetes.
“We are excited to enter the diabetes field and hope to bring a global breakthrough in the treatment of juvenile diabetes and potential cure.”
Kamada is currently undergoing a Phase I/II clinical trial with its FDA approved AAT by IV route of administration, for the treatment of type 1 diabetes, also known as juvenile diabetes.
Kamada plans to publish an interim and/or the final reports during 2012.
David Tsur, Chief Executive Officer of Kamada said: "We are excited to enter the diabetes field and hope to bring a global breakthrough in the treatment of juvenile diabetes and potential cure."
Kamada's AAT IV was granted FDA approval during July 2010 for the treatment of Alpha 1 deficiency and is exclusively marketed in the US by Baxter.